Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec;47(1):2556486.
doi: 10.1080/0886022X.2025.2556486. Epub 2025 Dec 11.

Immune mechanisms and immunomodulatory therapies in steroid-resistant nephrotic syndrome

Junchao Deng  1 , Lizhen Zhu  2 , Xiaoshi Zhu  1
Affiliations
Review

Immune mechanisms and immunomodulatory therapies in steroid-resistant nephrotic syndrome

Junchao Deng et al. Ren Fail. 2025 Dec.

Abstract

Steroid-resistant nephrotic syndrome (SRNS) is a complex and refractory kidney disease generally causing chronic kidney dysfunction, characterized by persistent proteinuria despite prolonged corticosteroid therapy. This review comprehensively explores the mechanisms of immunity driving SRNS, mainly focusing on the complex function network within immune cells, pro-inflammatory cytokines, and podocyte injury. Current immunosuppressive therapies show limited efficacy, prompting exploration of precision immunomodulatory strategies. Emerging approaches include IL-17 or low-dose IL-12 modulation, proteasome or CD38 blockade, C5/factor B inhibition, and Rho kinase or caspase inhibition. Additionally, personalized strategies leveraging genetic profiling and biomarker-guided therapies are advancing tailored interventions. These targeted therapies address SRNS heterogeneity while minimizing systemic immunosuppression, offering new promise for halting disease progression. Future directions emphasize combinatorial regimens and mechanistic stratification to optimize therapeutic outcomes.

Keywords: Immune mechanisms; Immunomodulation; Nephrotic syndrome; Pathogenesis; Podocyte.

Plain language summary

Focusing the immune mechanisms in SRNS, including podocyte injury and roles of lymphocytes.Discussions of the immunosuppressive therapies and limitations for related immune pathogenesis in SRNS.Exploration of novel immunomodulatory and personalized therapies against specific immune mechanisms in SRNS.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
Current and emerging therapies for SRNS.
See this image and copyright information in PMC

References

    1. Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38(3):877–919. doi: 10.1007/s00467-022-05739-3. - DOI - PMC - PubMed
    1. Tullus K, Webb H, Bagga A.. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health. 2018;2(12):880–890. doi: 10.1016/s2352-4642(18)30283-9. - DOI - PubMed
    1. Li S, He C, Sun Y, et al. Clinical characteristics and prognosis of steroid-resistant nephrotic syndrome in children: a multi-center retrospective study. Ital J Pediatr. 2024;50(1):242. doi: 10.1186/s13052-024-01817-4. - DOI - PMC - PubMed
    1. Banh THM, Hussain-Shamsy N, Patel V, et al. Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clin J Am Soc Nephrol. 2016;11(10):1760–1768. doi: 10.2215/cjn.00380116. - DOI - PMC - PubMed
    1. Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol. 2017;28(10):3055–3065. doi: 10.1681/asn.2016101121. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources